SCHEMBL9980215

SCHEMBL9980215

CCc1ccc2c3c(ccc2c1)-c1ccc2cc(CC)ccc2c1OC3

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.39
CYP2A6 P11509 1/20 0.39
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36
ELANE P08246 1/20 0.33
PARP1 P09874 1/20 0.33
NPC1 O15118 2/20 0.32
ALDH1A1 P00352 2/20 0.32
LMNA P02545 2/20 0.32
RAB9A P51151 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
MAPT P10636 1/20 0.32
MAPK1 P28482 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ESRRB O95718 1/20 0.32
ESRRA P11474 1/20 0.32
MEN1 O00255 1/20 0.31
GAA P10253 1/20 0.31
HPGD P15428 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17656233 0.93 ESR1 (0.35) CYP1A2CYP2A6ESR1ESR2ALDH1A1
SCHEMBL9980283 0.85 ESRRB (0.39) CYP1A2CYP2A6ELANEPARP1NPC1
SCHEMBL2757073 0.85 CYP1A2 (0.39) CYP1A2CYP2A6ELANEPARP1NPC1
SCHEMBL2756803 0.82 CYP1A2 (0.39) CYP1A2CYP2A6ELANEPARP1SMN1; SMN2
SCHEMBL15463301 0.81 CYP1A2 (0.35) CYP1A2CYP2A6ELANEPARP1MAPT
SCHEMBL15463302 0.81 ESRRB (0.36) CYP1A2CYP2A6ELANEPARP1LMNA
SCHEMBL14985614 0.80 ESR1 (0.41) CYP1A2CYP2A6ESR1ESR2ALDH1A1
SCHEMBL2756603 0.78 CYP1A2 (0.38) CYP1A2CYP2A6ELANENPC1ALDH1A1
SCHEMBL15368412 0.78 GAA (0.33) CYP1A2CYP2A6ELANEPARP1ALDH1A1
SCHEMBL14985621 0.78 ESRRB (0.36) CYP1A2CYP2A6ELANEPARP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120157404-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157404-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 CYP1A2 3826/4885CYP2A6 2659/4885ESR1 4094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.